• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Zevra Therapeutics, Inc. - Common Stock (NQ:ZVRA)

    10.59 -0.38 (-3.51%)
    Delayed Quote Updated: 12:28 PM EDT, Oct 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 314,293
    Open 10.91
    Bid (Size) 10.57 (300)
    Ask (Size) 10.60 (300)
    Prev. Close 10.97
    Today's Range 10.55 - 10.96
    52wk Range 8.010 - 15.04
    Shares Outstanding 33,932,639
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Zevra Therapeutics Q2 Earnings Call Highlights ↗
    Zevra Therapeutics (NASDAQ:ZVRA) reported second-quarter 2026 net revenue of $39.7 million, up 53% from $25.9 million a year earlier, driven primarily by U.S. sales of its Niemann-Pick disease type C... 
    Via MarketBeat
    Topics Earnings

    Performance

    YTD
    +26.9%
    +26.9%
    1 Month
    -9.8%
    -9.8%
    3 Month
    -23.4%
    -23.4%
    6 Month
    +12.5%
    +12.5%
    1 Year
    +11.3%
    +11.3%

    More News

    Read More
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)
    From Levi & Korsinsky, LLP
    Via Business Wire
    Zevra Therapeutics (NASDAQ:ZVRA) Shares Surge After Blowout Q1 Earnings Beat ↗
    Via Chartmill
    Zevra Therapeutics Inc (NASDAQ:ZVRA) Stock Surges 21% After Blowing Past Q4 Earnings Estimates ↗
    Via Chartmill
    News headline image
    ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law
    From Schall, Brown & Schwartz LLP
    Via Business Wire
    These stocks are gapping in today's session ↗
    Via Chartmill
    These stocks are moving in today's pre-market session ↗
    Via Chartmill
    News headline image
    Zevra (ZVRA) Q1 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings Intellectual Property
    News headline image
    Earnings Scheduled For November 5, 2025 ↗
    Via Benzinga
    News headline image
    Why Zevra Therapeutics Stock Zoomed 21% Higher Today ↗
    Via The Motley Fool
    Gapping stocks in Tuesday's session ↗
    Via Chartmill
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Nasdaq, S&P 500 Futures Turn Green On Iran War De-Escalation Signals: Why NVDA, ORCL, JOBY, VRTX, ZVRA Are On Traders' Radar Today ↗
    Via Stocktwits
    Topics Artificial Intelligence ETFs Government
    News headline image
    Dow, S&P 500, Nasdaq Futures Dip After Wall Street Rebound: Why SLS, ZVRA, RLMD, USO, CASY Are Trending After-Hours ↗
    Via Stocktwits
    Topics ETFs Government Stocks
    News headline image
    ZVRA Stock Soars On Upbeat Q4 Results, Optimism For EMA Approval Of Niemann-Pick Disease Treatment ↗
    Via Stocktwits
    Top movers in Monday's after hours session ↗
    Via Chartmill
    News headline image
    Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
    From Johnson Fistel, PLLP
    Via Business Wire
    News headline image
    This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Zevra (ZVRA) Q3 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Top Stocks With Earnings This Week: Joby, IonQ, AMD and More ↗
    Via Benzinga
    News headline image
    Zevra Therapeutics' Stock Soars on Strong Performance and Strategic Wins: What It Means for Investors
    Via MarketMinute
    News headline image
    Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga

    Frequently Asked Questions

    Is Zevra Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Zevra Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Zevra Therapeutics, Inc. - Common Stock trade on?
    Zevra Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Zevra Therapeutics, Inc. - Common Stock?
    The ticker symbol for Zevra Therapeutics, Inc. - Common Stock is ZVRA on the Nasdaq Stock Market
    What is the current price of Zevra Therapeutics, Inc. - Common Stock?
    The current price of Zevra Therapeutics, Inc. - Common Stock is 10.59
    When was Zevra Therapeutics, Inc. - Common Stock last traded?
    The last trade of Zevra Therapeutics, Inc. - Common Stock was at 10/01/26 12:28 PM ET
    What is the market capitalization of Zevra Therapeutics, Inc. - Common Stock?
    The market capitalization of Zevra Therapeutics, Inc. - Common Stock is 359.18M
    How many shares of Zevra Therapeutics, Inc. - Common Stock are outstanding?
    Zevra Therapeutics, Inc. - Common Stock has 359M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.